Roland Gordon-Beresford
Geen lopende functies
Profiel
Roland Gordon-Beresford worked as Director-IP & Regulatory Affairs at Celyad Oncology SA from 2012 to 2013.
He also worked as Chief Regulatory Affairs Officer at Novadip Biosciences SA. Dr. Gordon-Beresford holds a doctorate degree from Université Libre de Bruxelles.
Eerdere bekende functies van Roland Gordon-Beresford
| Bedrijven | Functie | Einde |
|---|---|---|
Novadip Biosciences SA
 Novadip Biosciences SA BiotechnologyHealth Technology Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium. | Algemeen Adviseur | - |
| CELYAD ONCOLOGY SA | Algemeen Adviseur | - |
Opleiding van Roland Gordon-Beresford
| Université Libre de Bruxelles | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CELYAD ONCOLOGY SA | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Novadip Biosciences SA
Novadip Biosciences SA BiotechnologyHealth Technology Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium. | Health Technology |
